Advances in the diagnosis and treatment of EBV associated lymphoproliferative disease in pediatric liver transplant recipients

References:

[1] Tran LT,Carullo PC,Banh D,et al.Pediatric liver transplantation:then and now[J].J Cardiothorac Vasc Anesth,2020,34(8):2028-2035.DOI:10.1053/j.jvca.2020.02.019.
[2] ?z?ay F.Lymphoproliferative disease after pediatric liver transplant[J].Exp Clin Transplant,2017,15(Suppl 2):79-81.DOI:10.6002/ect.TOND16.L22.
[3] Fishman JA.Infection in organ transplantation[J].Am J Transplant,2017,17(4):856-879.DOI:10.1111/ajt.14208.
[4] Jothimani D,Venugopal R,Vij M,et al.Post liver transplant recurrent and de novo viral infections[J].Best Pract Res Clin Gastroenterol,2020,46-47:101689.DOI:10.1016/j.bpg.2020.101689.
[5] Baker A,Frauca Remacha E,Torres Canizales J,et al.Current practices on diagnosis,prevention and treatment of post-transplant lymphoproliferative disorder in pediatric patients after solid organ transplantation:results of ern transplantchild healthcare working group survey[J].Children (Basel),2021,8(8):661.DOI:10.3390/children8080661.
[6] Dunmire SK,Hogquist KA,Balfour HH.Infectious mononucleosis[J].Curr Top Microbiol Immunol,2015,390(Pt 1):211-240.DOI:10.1007/978-3-319-22822-8_9.
[7] Qin T,Gu XQ,Jeong SS,et al.Impact of EBV infection and immune function assay for lymphoproliferative disorder in pediatric patients after liver transplantation:a single-center experience[J].Hepatobiliary Pancreat Dis Int,2020,19(1):3-11.DOI:10.1016/j.hbpd.2019.12.005.
[8] Hwang CS,Macconmara M,Desai DM.Pediatric abdominal organ transplantation[J].Surg Clin North Am,2019,99(1):73-85.DOI:10.1016/j.suc.2018.09.006.
[9] L’Huillier AG,Dipchand AI,Ng VL,et al.Posttransplant lymphoproliferative disorder in pediatric patients:characteristics of disease in ebv-seropositive recipients[J].Transplantation,2019,103(11):e369-e374.DOI:10.1097/TP.0000000000002898.
[10] Seo E,Kim J,Oh SH,et al.Epstein-Barr viral load monitoring for diagnosing post-transplant lymphoproliferative disorder in pediatric liver transplant recipients[J].Pediatr Transplant,2020,24(4):e13666.DOI:10.1111/petr.13666.
[11] Bunchorntavakul C,Reddy KR.Epstein-barr virus and cytomegalovirus infections of the liver[J].Gastroenterol Clin North Am,2020,49(2):331-346.DOI:10.1016/j.gtc.2020.01.008.
[12] 艾亮,张盛,王强,等.EB病毒相关性移植后淋巴组织增生性疾病生物标志物的相关进展[J].器官移植,2021,12(6):767-772.DOI:10.3969/j.issn.1674-7445.2021.06.019. Ai L,Zhang S,Wang Q,et al.Advances on biomarkers of EB virus-related posttransplant lymphoproliferative disease[J].Organ Transplantation,2021,12(6):767-772.DOI:10.3969/j.issn.1674-7445.2021.06.019.
[13] Huang JG,Tan M,Quak SH,et al.Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic asian cohort[J].Transpl Infect Dis,2018,20(1).DOI:10.1111/tid.12798.
[14] Bar?? Z,?z?ay F,Y?lmaz ??,et al.A single-center experience of post-transplant lymphoproliferative disorder (PTLD) cases after pediatric liver transplantation:Incidence,outcomes,and association with food allergy[J].Turk J Gastroenterol,2018,29(3):354-360.DOI:10.5152/tjg.2018.17731.
[15] Grimm KE,O’Malley DP.Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues[J].Ann Diagn Pathol,2019,38:6-10.DOI:10.1016/j.anndiagpath.2018.09.014.
[16] Tajima T,Hata K,Haga H,et al.Post-transplant lymphoproliferative disorders after liver transplantation:a retrospective cohort study including 1954 transplants[J].Liver Transpl,2021,27(8):1165-1180.DOI:10.1002/lt.26034.
[17] Song H,Guja KE,Iagaru A.(18)F-FDG PET/CT for Evaluation of Post-transplant lymphoproliferative disorder (PTLD)[J].Semin Nucl Med,2021,51(4):392-403.DOI:10.1053/j.semnuclmed.2020.12.009.
[18] Montes de Jesus FM,Glaudemans A,Tissing WJ,et al.(18)F-FDG PET/CT in the diagnostic and treatment evaluation of pediatric posttransplant lymphoproliferative disorders[J].J Nucl Med,2020,61(9):1307-1313.DOI:10.2967/jnumed.119.239624.
[19] Xu YF,Yang JG.Roles of F-18-Fluoro-2-Deoxy-Glucose PET/Computed tomography scans in the management of post-transplant lymphoproliferative disease in pediatric patient[J].PET Clin,2020,15(3):309-319.DOI:10.1016/j.cpet.2020.03.006.
[20] Guberina N,G?ckler A,Grueneisen J,et al.Assessment of Suspected Malignancy or Infection in Immunocompromised Patients After Solid Organ Transplantation by[(18)F]FDG PET/CT and[(18)F]FDG PET/MRI[J].Nucl Med Mol Imaging,2020,54(4):183-191.DOI:10.1007/s13139-020-00648-5.
[21] AbuSalah M,Gan SH,Al-Hatamleh M,et al.Recent advances in diagnostic approaches for epstein-barr virus[J].Pathogens,2020,9(3):226.DOI:10.3390/pathogens9030226.
[22] Chen HS,Ho MC,Hu RH,et al.Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation[J].J Formos Med Assoc,2019,118(9):1362-1368.DOI:10.1016/j.jfma.2018.12.007.
[23] Kanakry J,Ambinder R.The biology and clinical utility of ebv monitoring in blood[J].Curr Top Microbiol Immunol,2015,391:475-499.DOI:10.1007/978-3-319-22834-1_17.
[24] Bergallo M,Gambarino S,Pinon M,et al.EBV-encoded microRNAs profile evaluation in pediatric liver transplant recipients[J].J Clin Virol,2017,91:36-41.DOI:10.1016/j.jcv.2017.04.002.
[25] Wiesmayr S,Webber SA,Macedo C,et al.Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD[J].Eur J Immunol,2012,42(2):541-550.DOI:10.1002/eji.201141832.
[26] Huang YC,Lin SJ,Lin KM,et al.Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients’ survival[J].Blood,2016,128(12):1578-1589.DOI:10.1182/blood-2016-02-702530.
[27] Soriano-López DP,Alcántar-Fierros JM,Hernández-Plata JA,et al.A scheduled program of molecular screening for epstein-barr virus decreases the incidence of post-transplantation lymphoproliferative disease in pediatric liver transplantation[J].Transplant Proc,2016,48(2):654-657.DOI:10.1016/j.transproceed.2016.02.031.
[28] Kullberg-Lindh C,Saalman R,Olausson M,et al.Epstein-Barr virus DNA monitoring in serum and whole blood in pediatric liver transplant recipients who do or do not discontinue immunosuppressive therapy[J].Pediatr Transplant,2017,21(5).DOI:10.1111/petr.12875.
[29] Al Dabbagh MA,Gitman MR,Kumar D,et al.The role of antiviral prophylaxis for the prevention of epstein-barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients:a systematic review[J].Am J Transplant,2017,17(3):770-781.DOI:10.1111/ajt.14020.
[30] ?stensen AB,Sanengen T,Holter E,et al.No effect of treatment with intravenous ganciclovir on Epstein-Barr virus viremia demonstrated after pediatric liver transplantation[J].Pediatr Transplant,2017,21(6).DOI:10.1111/petr.13010.
[31] Cui X,Cao Z,Ishikawa Y,et al.Immunization with epstein-barr virus core fusion machinery envelope proteins elicit high titers of neutralizing activities and protect humanized mice from lethal dose ebv challenge[J].Vaccines (Basel),2021,9(3).DOI:10.3390/vaccines9030285.
[32] Cui X,Snapper CM.Epstein barr virus:development of vaccines and immune cell therapy for ebv-associated diseases[J].Front Immunol,2021,12:734471.DOI:10.3389/fimmu.2021.734471.
[33] Lindsay J,Othman J,Heldman MR,et al.Epstein-Barr virus posttransplant lymphoproliferative disorder:update on management and outcomes[J].Curr Opin Infect Dis,2021,34(6):635-645.DOI:10.1097/QCO.0000000000000787.
[34] Trappe RU,Dierickx D,Zimmermann H,et al.Response to rituximab induction is a predictive marker in b-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or r-chop consolidation in an international,prospective,multicenter phase ii trial[J].J Clin Oncol,2017,35(5):536-543.DOI:10.1200/JCO.2016.69.3564.
[35] Allen UD,Preiksaitis JK.Post-transplant lymphoproliferative disorders,Epstein-Barr virus infection,and disease in solid organ transplantation:guidelines from the american society of transplantation infectious diseases community of practice[J].Clin Transplant,2019,33(9):e13652.DOI:10.1111/ctr.13652.
[36] Dierickx D,Habermann TM.Post-transplantation lymphoproliferative disorders in adults[J].N Engl J Med,2018,378(6):549-562.DOI:10.1056/NEJMra1702693.
[37] Serinet MO,Jacquemin E,Habes D,et al.Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated,B-cell lymphoproliferative disease in pediatric liver transplant recipients[J].Journal of Pediatric Gastroenterology & Nutrition,2002,34(4):389.DOI:10.1001/archsurg.136.12.1386.
[38] Chiou FK,Beath SV,Patel M,et al.Hypogammaglobulinemia and bacterial infections following pediatric post-transplant lymphoproliferative disorder in the rituximab era[J].Pediatr Transplant,2019,23(6):e13519.DOI:10.1111/petr.13519.
[39] Gross TG,Bucuvalas JC,Park JR,et al.Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation[J].J Clin Oncol,2005,23(27):6481-6488.DOI:10.1200/JCO.2005.08.074.
[40] Gross TG,Orjuela MA,Perkins SL,et al.Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD):a children’s oncology group report[J].Am J Transplant,2012,12(11):3069-3075.DOI:10.1111/j.1600-6143.2012.04206.x.
[41] Taj MM,Maecker-Kolhoff B,Ling R,et al.Primary post-transplant lymphoproliferative disorder of the central nervous system:characteristics,management and outcome in 25 paediatric patients[J].Br J Haematol,2021,193(6):1178-1184.DOI:10.1111/bjh.17398.
[42] O’Reilly RJ,Prockop S,Hasan AN,et al.Virus-specific T-cell banks for ’off the shelf’ adoptive therapy of refractory infections[J].Bone Marrow Transplant,2016,51(9):1163-1172.DOI:10.1038/bmt.2016.17.
[43] Chiou FK,Beath SV,Wilkie GM,et al.Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children[J].Pediatr Transplant,2018,22(2).DOI:10.1111/petr.13133.
[44] Schuster SJ,Bishop MR,Tam CS,et al.Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma[J].N Engl J Med,2019,380(1):45-56.DOI:10.1056/NEJMoa1804980.
[45] Wang T,Feng M,Luo C,et al.Successful treatment of pediatric refractory burkitt lymphoma PTLD after liver transplantation using anti-cd19 chimeric antigen receptor t-cell therapy[J].Cell Transplant,2021,30:963689721996649.DOI:10.1177/0963689721996649.
[46] Nakid-Cordero C,Baron M,Guihot A,et al.Natural killer cells in post-transplant lymphoproliferative disorders[J].Cancers (Basel),2021,13(8).DOI:10.3390/cancers13081836.
[47] Schiefer AI,Salzer E,Füreder A,et al.PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence:An inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories[J].Cancer Med,2019,8(10):4656-4668.DOI:10.1002/cam4.2394.
[48] Bollard CM,Cohen JI.How I treat T-cell chronic active Epstein-Barr virus disease[J].Blood,2018,131(26):2899-2905.DOI:10.1182/blood-2018-03-785931.